Free shipping on all orders over $ 500

MGCD0103

Cat. No. M1790
MGCD0103 Structure
Synonym:

Mocetinostat

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 45  USD45 In stock
5mg USD 40  USD40 In stock
10mg USD 55  USD55 In stock
50mg USD 110  USD110 In stock
100mg USD 175  USD175 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

MGCD0103 (Mocetinostat) is a novel HDAC inhibitor, highly specific for classes I and IV HDACs. It is well-tolerated and exhibits favorable pharmacokinetic and pharmacodynamic profiles, demonstrating target inhibition and clinical responses. MGCD0103 (Mocetinostat) has been recently shown to exhibit various effects on non-histone targets on cancer cells. The latest preclinical studies have demonstrated that MGCD0103 can induce both cell death and autophagy.

Customer Product Validations & Biological Datas
Source Int J Clin Exp Pathol (2015). Figure 3. MGCD0103
Method i.v.
Cell Lines liver cells
Concentrations 20, 40, 80 mg/kg
Incubation Time 7 days
Results According to the pathological changes of liver at difference dosage, MGCD0103 is hepatotoxic and its toxity is dosedependent.
Protocol (for reference only)
Cell Experiment
Cell lines HCT116, HCT15, HT29, DU145, MDA-mb231, A549 cells line
Preparation method Cell Viability Assay
Cells in 96-well plates were incubated with compounds at various concentrations for 72 h at 37°C in 5% CO2. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) was added at a final concentration of 0.5 mg/mL and incubated with the cells for 4 h before an equal volume of solubilization buffer [50% N,N-dimethylformamide, 20% SDS (pH 4.7)] was added. After overnight incubation, solubilized dye was quantified by reading at 570 nm using a reference at 630 nm. Absorbance values were converted to cell numbers according to a standard growth curve of the relevant cell line. The concentration which reduced cell numbers to 50% relative to DMSO-treated cells was determined as MTT IC50.
Concentrations 0~100 μ M
Incubation time 72 h
Animal Experiment
Animal models Female CD-1 nude mice
Formulation PBS acidified with 0.1 N HCl or PEG400/0.2 N HCl saline, 40:60
Dosages daily for at least 2 weeks
Administration p.o.
Chemical Information
Molecular Weight 396.44
Formula C23H20N6O
CAS Number 726169-73-9
Solubility (25°C) DMSO 20 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Boumber Y, et al. Expert Opin Investig Drugs. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.

[2] Sung V, et al. Cancer Sci. Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells.

[3] Sikandar S, et al. Oncotarget. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling.

[4] Moreno-Bost A, et al. Cytotherapy. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.

[5] Buglio D, et al. Br J Haematol. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.

[6] Chia K, et al. Mol Pharmacol. The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity.

[7] Fournel M, et al. Mol Cancer Ther. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

Related HDAC Products
Ac-Arg-Gly-Lys(Ac)-AMC

Ac-Arg-Gly-Lys(Ac)-AMC is a substrate for HDAC.

Chlamydocin

Chlamydocin, a fungal metabolite, is a highly potent HDAC inhibitor, with an IC50 of 1.3 nM.

HDAC-IN-30

HDAC-IN-30 is a novel multi-target HDAC inhibitor, including HDAC1 (IC50=13.4 nM),HDAC2 (IC50=28.0 nM), HDAC3 (IC50=9.18 nM), HDAC6 (IC50=42.7 nM), HDAC8 (IC50=131 nM).

Ac-Arg-Gly-Lys(Ac)-AMC acetate

Ac-Arg-Gly-Lys(Ac)-AMC acetate is a substrate for histone deacetylase (HDAC) and can be used in a novel fluorescent assay for HDAC activity.

JPS014 TFA

JPS014 TFA is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras (PROTAC).

  Catalog
Abmole Inhibitor Catalog




Keywords: MGCD0103, Mocetinostat supplier, HDAC, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.